Court seen as “exceeding expectations” | Experts urge caution, emphasising that confident and reliable court judgments are needed | High-stakes patent litigation, especially in pharmaceuticals, remains predominantly within national courts.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
7 July 2026 Focusing on technology and life sciences clients, the new San Fran-based Debevoise & Plimpton hire brings both in-house and private practice litigation experience across trade secrets and commercial disputes.
6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.
3 July 2026 A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.